Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Telix Pharmaceuticals Ltd. securities for the period between February 21, 2025, and August 28, 2025, due to alleged misleading statements made by the company [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Telix Pharmaceuticals made materially false and misleading statements regarding its progress with prostate cancer therapeutic candidates and the quality of its supply chain and partners [5]. - Investors are entitled to compensation without any out-of-pocket fees through a contingency fee arrangement if they purchased Telix securities during the class period [2]. - A lead plaintiff must move the Court by January 9, 2026, to represent other class members in the litigation [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, highlighting their expertise in the field [4].

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Telix Pharmaceuticals Limited ("Telix†or the "Company†) (NASDAQ: TLX) securities between February 21, 2025 and August 28, 2025, inclusive (the "Class Period†). Telix investors have until January 9, 2026 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS. ...

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited for securities fraud, alleging that the company made materially false statements and failed to disclose adverse facts about its business and operations during the class period from February 21, 2025, to August 28, 2025 [1][5]. Summary by Sections Company Disclosures - On July 22, 2025, Telix disclosed it received a subpoena from the U.S. Securities and Exchange Commission (SEC) regarding its disclosures related to prostate cancer therapeutic candidates, leading to a stock price drop of $1.70, or 10.4%, closing at $14.58 on July 23, 2025 [3]. - On August 28, 2025, Telix announced it received a Complete Response Letter (CRL) from the FDA concerning its Biologics License Application (BLA) for TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls (CMC) package. This announcement caused the stock price to fall by $1.95, or 16.1%, closing at $10.15 on the same day [4]. Allegations in the Lawsuit - The lawsuit alleges that throughout the class period, Telix's management made materially false and misleading statements and failed to disclose critical adverse facts, including: 1. Overstating the progress made on prostate cancer therapeutic candidates [5]. 2. Overstating the quality of Telix's supply chain and partners [5]. 3. Positive statements about the company's business and prospects were materially misleading and lacked a reasonable basis [5].

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds purchasers or acquirers of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) (“Telix”) American Depositary Shares (“ADS”) that a securities class action has been filed. The class period is between February 21, 2025 and August 28, 2025, inclusive. Investors have until January 9, 2026 to seek appointment as lead plaintiff. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations: The lawsuit alleges viol ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - November 12, 2025 ...

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLXNovember 12, 2025 3:12 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 12, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between Fe ...

Core Viewpoint - Telix Pharmaceuticals Limited is facing a securities class action lawsuit following significant stock declines due to a regulatory subpoena and an FDA rejection letter [1] Group 1: Legal Proceedings - The lawsuit, titled Thomas v. Telix Pharmaceuticals Ltd., seeks to represent investors who acquired Telix securities between February 21, 2025, and August 28, 2025 [3] - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [2][8] Group 2: Company Statements and Allegations - The litigation focuses on Telix's statements regarding its prostate cancer therapeutic candidates TLX591 and TLX592, as well as its kidney cancer detection candidate Zircaix [4] - During the class period, Telix claimed progress in its therapeutic pipeline and emphasized its global manufacturing capabilities as a competitive advantage [5] - The lawsuit alleges that Telix made false and misleading statements, overstating the progress of its prostate cancer candidates and the quality of its supply chain [5] Group 3: Regulatory Issues - On July 22, 2025, Telix disclosed an SEC investigation into its disclosures related to the development of its prostate cancer therapeutic candidates, leading to a sharp decline in stock price [6] - On August 28, 2025, Telix received a Complete Response Letter from the FDA for its Zircaix BLA, citing deficiencies in manufacturing and requesting additional data [7]

Accessibility StatementSkip Navigation PHILADELPHIA, Nov. 12, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than Januar ...

ATLANTA, Nov. 12, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (“Telix”) (NASDAQ: TLX). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Telix’s business, operations, and prospects, including allegations that: (1) Defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) Defendants ...

Core Viewpoint - Telix Pharmaceuticals Limited is facing a lawsuit for alleged violations of securities laws, which may impact its financial standing and investor confidence [1] Group 1: Company Overview - Telix Pharmaceuticals Limited is currently involved in legal proceedings related to securities law violations, indicating potential governance and compliance issues [1] Group 2: Legal Implications - The lawsuit suggests that there may be significant legal risks associated with Telix Pharmaceuticals, which could affect its market performance and investor relations [1]